Summary of Product Characteristics
1 NAME OF THE VETERINARY MEDICINAL PRODUCT
Cydectin 10% LA Solution for Injection for Cattle
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
Each ml contains: Active substance
Moxidectin
Excipeints
100 mg
Benzyl Alcohol (E1519)
70 mg
For a full list of excipients, see section 6.1
3 PHARMACEUTICAL FORM
Solution for injection. Clear yellow liquid.
4 CLINICAL PARTICULARS
4.1 Target Species
Cattle.
4.2 Indications for use, specifying the target species
In cattle weighing from 100 to 500 kg body weight, treatment and prevention of mixed infestations by the following gastro-intestinal nematodes, respiratory nematodes and certain arthropod parasites :
Adult and immature gastro-intestinal nematodes :
. Haemonchus placei
. Haemonchus contortus
. Ostertagia ostertagi (including inhibited larvae)
. Trichostrongylus axei
. Trichostrongylus colubriformis
. Nematodirus helvetianus (adults only)
. Nematodirus spathiger
. Cooperia surnabada
. Cooperia oncophora
. Cooperia pectinata
. Cooperia punctata
. Oesophagostomum radiatum
. Bunostomum phlebotomum (adults only)
. Chabertia ovina (adults only)
. Trichuris spp. (adults only)
Adult and immature respiratory tract nematode
. Dictyocaulus viviparus
Warble grubs (migrating larvae)
. Hypoderma bovis
. Hypoderma lineatum
Lice
. Linognathus vituli
. Haematopinus eurysternus
. Solenopotes capillatus
. Bovicolabovis (aid in control)
Mange mites
. Sarcoptes scabiei
. Psoroptes ovis
. Chorioptes bovis (aid in control)
The drug has a persistent action and protects cattle for a certain duration against infection or re-infection with the following parasites for the period indicated:
Protection period (days)
Species
Dictyocaulus viviparus 120
Ostertagia ostertagi 120
Haemonchus placei 90
Oesophagostomum radiatum 150
Trichostrongylus axei 90
Linognathus vituli 133
The product is effective against Hypoderma larvae at the time of treatment but its persistent activity against Hypoderma has not been evaluated. If the product is given before the end of the fly season complimentary treatment with a product effective against Hypoderma may be required.
Persistent efficacy periods have not been established for parasite species other than those included in the above list. Therefore, re-infection of animals on pasture contaminated by parasites other than these remains possible before the end of the 90 day minimum persistency period demonstrated for specific species.
4.3 Contraindications
Do not use in animals less than 100 kg bodyweight or greater than 500 kg.
Do not inject the product by intravascular route. Intravascular injection may result in ataxia, paralysis, convulsions, collapse and death. To prevent any intravascular injection, carefully follow the administration procedure described in item “Amounts to be administered and administration route”.
4.4 Special warnings for each target species
Care should be taken to avoid the following practices, because they increase the risk of development of resistance and could ultimately result in ineffective therapy:
Too frequent and repeated use of anthelmintics from the same class, over an extended period of time;
Under-dosing which may due to underestimation of body weight, misadministration of the product, or lack of calibration of the dosing device (If any).
Suspected clinical cases of resistance to anthelmintics should be further investigated using appropriate tests (e.g. Faecal Egg Count Reduction Test).Where the results of the test(s) strongly suggest resistance to a particular anthelmintic, an anthelmintic belonging to another pharmacological class and having a different mode of action should be used.
4.5 Special precautions for use
Special precautions for use in animals
In order to prevent abscesses, a strict aseptic technique is recommended.
CYDECTIN 10% LA for Cattle has been formulated specifically for subcutaneous injection in dorsal surface of the ear of cattle and must not be given by any other route of administration or to any other species.
To avoid possible secondary reactions by the death of Hypoderma larvae in the spine or the oesophagus of animals, it is recommended to administer a product effective against Hypoderma larvae after the end of fly activity and before the larvae reach their resting sites. Consult your veterinary surgeon on the correct timing of this treatment.
Immunity to nematodes depends on adequate exposure to infection. Although not normally the case, circumstances could occur in which anthelmintic control measures might increase the vulnerability of cattle to re-infection. Animals may be at risk towards the end of their first grazing season, particularly if the season is long, or in the following year if they move onto heavily contaminated pasture. In such instances, further control measures may be necessary. Special precautions to be taken by the person administering the veterinary medicinal product to animals
Avoid direct contact with skin and eyes.
Wash hands after use.
Do not smoke, drink or eat while handling the product.
Take care to avoid self-injection. Advice to Medical Practitioners in case of accidental self injection: Treat symptomatically.
4.6 Adverse reactions (frequency and seriousness)
On rare occasions, immediate or delayed swelling can be observed at the injection site, these swellings may further develop into abcesses (approx. 1 % of cases). The frequency of injection site swellings tends to be higher in the heavier animals. These side effects generally disappear without treatment, within 14 days after administration, some may persist for up to 5 weeks in a number of animals (<5 %) and in very rare occasions longer.
On rare occasions, depression and ataxia can be observed after injection.
In case of hypersensitivity reactions, a symptomatic treatment should be applied.
The frequency of adverse reactions is defined using the following convention:
very common (more than 1 in 10 animals displaying adverse reactions during the course of one treatment) common (more than 1 but less than 10 animals in 100 animals) uncommon (more than 1 but less than 10 animals in 1,000 animals) rare (more than 1 but less than 10 animals in 10,000 animals) very rare (less than 1 animal in 10,000 animals, including isolated reports).
4.7 Use during pregnancy, lactation or lay
Can be used during pregnancy. However, note 4.3. Contra-Indications.
4.8 Interaction with other medicinal products and other forms of interaction
The effects of GABA agonists are increased by moxidectin.
4.9 Amounts to be administered and administration route
Dosage is 0.5 ml/50 kg bodyweight, equivalent to 1.0 mg moxidectin/kg bodyweight, given by a single subcutaneous injection in the ear using an 18 gauge, 25 – 40 mm hypodermic needle. The 50ml vial stoppers must not be broached more than 20 times. Use automatic syringe equipment for the 200 ml vial.
Shake well before use.
To ensure administration of a correct dosage, body weight should be determined as accurately as possible; accuracy of the dosing should be checked.
The injection should be given subcutaneously in the loose tissues on the dorsal surface of the ear, just distal to the distal edge of the auricular cartilage.
The dorsal (outer) surface of the ear should first be cleansed with antiseptic and allowed to briefly air dry. Palpate the edge of the auricular cartilage closest to the head, on the dorsal (hairy) surface of the ear. From this landmark, taking care to avoid blood vessels (artery, vein), the needle should be inserted subcutaneously starting at a point approximately 3 to 3.5 cm distal to this edge (away from the head), and directed towards the base of the ear, and the needle advanced to the hub. At this point, gently aspirate the syringe to confirm that the needle is not in a blood vessel.
Upon injection, the resulting depot should reside just distal to the edge of the auricular cartilage.
Following administration, the needle is withdrawn from the skin as pressure is applied for several seconds with the thumb at the point of insertion.
Due to the long lasting protection against Dictyocaulus viviparus and the stomach worms, Ostertagia ostertagi and Haemonchus placei, a single treatment with the formulation at turn-out helps control parasitic bronchitis (lungworm) and parasitic gastro-enteritis throughout the grazing season by reducing the build-up of infective larvae on pasture associated with these parasites. For best results the injection should be given to each calf of target weight to be grazed together immediately prior to being turned out to pasture. Animals should be set stocked throughout the grazing season or moved to a pasture which has not been grazed by other cattle earlier in the season.
Diagram: Ear injection procedure
4.10 Overdose (symptoms, emergency procedures, antidotes), if necessary
Reactions at the injection site have to be expected more frequently and severe depending on the injected volume. Systemic signs of overdoses are consistent with the mode of action of moxidectin. These signs are manifested as transient salivation, depression, drowsiness and ataxia 24 to 36 hours post-treatment. The systemic signs usually disappear within 36 to 72 hours without treatment. At doses >3 times the recommended dose divided on both ears, the systemic signs included recumbency, muscle tremor, ruminal tympany and dehydration, which were resolved after treatment with fluids. The systemic signs can last for a few days to ten days. There is no specific antidote. 4.11 Withdrawal Period(s)
Meat and offal : 108 days.
Milk : Not permitted for use in lactating animals producing milk for human consumption or industrial purposes or within 80 days of expected parturition.
The withdrawal period is based solely on a single injection at the ear site of injection.
5 PHARMACOLOGICAL or IMMUNOLOGICAL PROPERTIES
ATCvet Code QP 54 AB 02
Pharmacotherapeutic group: Endectocides
5.1 Pharmacodynamic properties
Moxidectin is an endectocide active against a wide range of internal and external parasites and is a second generation macrocyclic lactone of the milbemycin family.
Moxidectin interacts with GABA receptors and chloride channels.
The net effect is to open the chloride channels on the postsynaptic junction to allow the inflow of chloride ions and induce an irreversible resting state. This results in flaccid paralysis and eventual death of parasites exposed to the drug.
5.2 Pharmacokinetic properties
Moxidectin is absorbed following subcutaneous injection with maximum blood concentrations being achieved 24 to 48 hours post injection. The drug is distributed throughout the body tissues but due to its lipophilicity it is concentrated mainly in the fat. The depletion half life in fat is 26 – 32 days.
Moxidectin undergoes limited biotransformation by hydroxylation in the body. The only significant route of excretion is the faeces.
6 PHARMACEUTICAL PARTICULARS
6.1 List of excipients
Benzyl alcohol (E1519)
Sorbitan Monooleate (Crill 4HP)
Propylene Glycol Dicaprylate/Dicaprate
6.2 Incompatibilities
None known.
Not to be mixed with other Veterinary Medicinal Products before administration.
6.3 Shelf-life
Shelf life of the veterinary medicinal product as packaged for sale: 3 years. Shelf life after first opening the immediate packaging: 28 days.
6.4 Special precautions for storage
Do not store above 25°C. Protect from light.
6.5 Nature and composition of immediate packaging
Naure of the primary container;
HDPE vial
Chlorinated butyl rubber stopper
Aluminium flip off seal(50 ml vial) Aluminium seal (200 ml)
Presentations to be sold and identification numbers: Box containing 1 vial of 50ml size
Box 1 vial of 200ml size
6.6 Special precautions for the disposal of unused veterinary medicinal products or waste materials
Extremely Dangerous for fish and aquatic organisms. Do not contaminate ponds, waterways or ditches with the product or empty container.
Any unused veterinary medicinal products or waste materials derived from such veterinary medicinal products should be disposed of in accordance with local requirements.
7 MARKETING AUTHORISATION HOLDER
Zoetis Ireland Limited
25/28 North Wall Quay
Dublin 1
Ireland
8 MARKETING AUTHORISATION NUMBER(S)
VPA 10438/016/001
9 DATE OF THE FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION
Date of first authorisation: 21st October 2005
Date of last renewal: 17th January 2010
10 DATE OF REVISION OF THE TEXT
July 2016
Menu
